Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in pancreatic cancer.

Created on 01 Nov 2026

Authors

Kui-Jin Kim, Cheng Hyun Lee, Milang Nam, Hee Young Na, Ji Hea Sung, Bo-Ram Park, Sung-Hyun Hwang, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Zev A Wainberg, Jin Won Kim

Published in

Cancer gene therapy. Oct 31, 2026. Epub Oct 31, 2026.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a poor prognosis and a high propensity for metastasis. Analysis of TCGA data revealed that PAK4 overexpression was associated with inferior survival outcomes in PDAC patients. In this preclinical study, PAK4-amplified PDAC cells significantly enhanced migratory capacity compared to wild-type cells. Knockdown of PAK4 in these cells suppressed migration by increasing and stabilizing E-cadherin, accompanied by decreased Cdc42 activity. Conversely, constitutive expression of Flag-PAK4 in wild-type cells reduced E-cadherin levels while promoting cell migration, invasion, and motility through elevated Cdc42 activity. Immunoprecipitation and immunofluorescence analysis confirmed that PAK4 physically interacted with E-cadherin and Cdc42, with evident colocalization of these proteins. In an orthotopic PDAC mouse model, PAK4 knockdown reduced primary tumor burden and prevented malignant ascites, mediated by E-cadherin activation and stabilization. Notably, an inverse correlation between PAK4 and E-cadherin expression was also observed in pancreatic cancer patients' specimens. Collectively, these findings suggest that PAK4 drives invasive and metastatic phenotypes in PDAC by modulating E-cadherin and that targeting PAK4 may represent a promising therapeutic strategy for PDAC treatment.

PMID:
42966774
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement